Drug Search Results
More Filters [+]

NEUROTROPHIN-3

Alternative Names: neurotrophin-3, nerve growth factor 2, neurotrophic factor
Latest Update: 2024-10-15
Latest Update Note: News Article

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Herantis Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NEUROTROPHIN-3

Countries in Clinic: Germany, Poland

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ASK-PD5-CS201

P2

Unknown Status

Parkinson's Disease

2027-12-01

Long-Term Follow-up Safety After DDS Implantation with/without CDNF Infusions

P2

Active, not recruiting

Parkinson's Disease

2023-12-30

Recent News Events